Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PIV3

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Sanofi reports improved patient outcomes from high-dose influenza vaccine

Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

- PMLiVE

Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

Sha joined Sanofi in 2019 and takes up her new role with immediate effect

- PMLiVE

Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

More than 180,000 people worldwide are diagnosed with the disease every year

- PMLiVE

Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

The drug is already approved in the EU across three other multiple myeloma indications

- PMLiVE

Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

- PMLiVE

Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

The deal includes an early-stage combination vaccine candidate for RSV and hMPV

- PMLiVE

Merck to expand respiratory disease portfolio with $10bn Verona acquisition

The deal includes a drug approved in the US for chronic obstructive pulmonary disease

- PMLiVE

Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links